1
Moreau Jacques Pierre, Kitchell Judith P: Delivery system.. Biomeasure, February 1, 1989: EP0301856-A2 (180 worldwide citation)

A delivery system for agents, such as therapeutic agents, or other substances includes a biodegradable polymer and the agent or substance. The delivery system is coated with a barrier substance that decreases the quantity of the agent release from the system, compared to the quantity of the agent re ...


2
Oshlack Benjamin, Chasin Mark: Orally administrable opioid formulations having extended duration of effect.. Euro Celtique, April 12, 1995: EP0647448-A1 (161 worldwide citation)

Sustained release oral solid dosage forms of opioid analgesics are provided as multiparticulate systems which are bioavailable and which provide effective blood levels of the opioid analgesic for at least about 24 hours. A unit dose of the opioid analgesic contains a plurality of substrates includin ...


3
W Mark Eickhoff, Karl R Mueller, David A Engers: Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids. NawoSystems L L C, Rudman & Balogh, October 1, 1996: US05560931 (96 worldwide citation)

Nanoparticulate crystalline drug substances formulated in an aqueos phase emulsified in oil, are able to be made at less than 1000 nm size and provide increased bioavailability and lymphatic uptake following oral administration.


4
Heafield Joanne, Knott Trevor John, Leslie Stewart Thomas, Malkowska Sandra Therese A, Miller Ronald Brown, Prater Derek Allan, Smith Kevin John, Chasin Mark, Goldenheim Paul, Oshlack Benjamin, Pedi Frank Jr, Sackler Richard, Kaiko Robert: Sustained release compositions containing morphine.. Euro Celtique, February 1, 1995: EP0636370-A1 (89 worldwide citation)

In order to provide a sustained release pharmaceutical formulation containing morphine which is suitable for administration on a once daily basis, in a first aspect, an orally administrable sustained release dosage unit form contains morphine, or a pharmaceutically acceptable salt thereof, as active ...


5
Mougin Nathalie, Mondet Jean: Composition contenant a dispersion of polymer particles in a non aqueous medium. Oreal, December 27, 1996: EP0749747-A1 (88 worldwide citation)

Compsns. (I) comprise, in a medium acceptable for cosmetic, pharmaceutical and/or hygienic use, a dispersion of particles of at least one polymer surface-stabilised by a stabilising agent in a non-aq. medium, provided that: (a) the non aq. medium is composed of at least one non-aq. liq. chosen from ...


6
Danley Dennis Edward, Gelfand Robert Alan, Geoghegan Kieran Francis, Yesook Kim, Lambert William Joseph, Hong Qi: Prolonged delivery of insulinotropin (glp-1). Pfizer, October 12, 1994: EP0619322-A2 (84 worldwide citation)

There are disclosed methods for the treatment of non-insulin dependent diabetes mellitus in a mammal comprising the prolonged administration of GLP-1(7-37), and related peptides. Also disclosed are compositions to prolong the administration of the peptides.


7
Hauser Pierre Smithkline Beech, Voet Pierre Smithkline Beecham, Slaoui Moncef Smithkline Beech, Garcon Johnson Nathalie Marie, Desmons Pierre Smithkline Beec: Vaccine compositions containing 3-o deacylated monophosphoryl lipid a. Smithkline Beecham Biolog, January 3, 1996: EP0689454-A1 (76 worldwide citation)

Novel vaccine compositions comprising small particles of 3-O-deacylated monophosphoryl lipid A are provided. In particular the particle size is below 120 nm. Such vaccine compositions have superior immunological properties.


8
Pope David G, Wilkinson Paul K: A system for enhancing the water dissolution rate and solubility of poorly soluble drugs.. Merck & Co, April 30, 1986: EP0179583-A1 (70 worldwide citation)

Novel anhydrous compositions comprise a poorly water-soluble drug and a surfactant having enhanced dissolution rate and solubility. The drug-surfactant ratio in the composition is such that dissolution and solubility of the drug are enhanced. The compositions disclosed herein are useful in the treat ...


9
Miller Ronald Brown, Leslie Stewart Thomas, Malkowska Sandra Therese Antoi, Smith Kevin John, Wimmer Walter, Winkler Horst, Hahn Udo, Prater Derek Allan: Controlled release formulation containing tramadol.. Euro Celtique, November 17, 1994: EP0624366-A1 (68 worldwide citation)

A controlled release preparation for oral administration contains tramadol, or a pharmaceutically acceptable salt thereof, as active ingredient.


10
Modi Pankaj: Formulations a base de phospholipides, Phospholipid formulations. Modi Pankaj, Generex Pharmaceuticals, PERRY CURRIER, April 24, 2001: CA2181390 (66 worldwide citation)

A medicinally active formulation contains i) at least three compounds selected from the group consisting of egg phosphatidylcholine, dilauryl phosphatidylcholine, dimyristoyl phosphatidylcholine, dipalmitoyl phosphatidylcholine, dioleoyl phosphatidylcholine, dimyristoyl phosphatidylglycerol, dipalmi ...